New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...

BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity ...

In a recent Q&A hosted by Susan Thornton, CEO of the Cutaneous Lymphoma Foundation, a patient advocacy group, Dr. Kim shared her gratitude to clinical trial participants and emphasized the urgent need ...

Under the new law, anyone in Montana can legally access drugs that have passed just one phase 1 clinical trial.

The trial is evaluating EB103, which is a CD19-redirected ARTEMIS® T-cell therapy, in adult patients (aged 18 and older) with ...

The analysts are supporting the company’s potential in the broader mental health sector, demonstrating the transformative ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Specialty televisits remain common in the Veterans Health Administration following the COVID-19 pandemic, suggesting they will remain an important ongoing care modality for many patients.

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.